Doxercalciferol

What is Doxercalciferol?

Doxercalciferol is a synthetic analog of vitamin D2, specifically designed to address complications arising from kidney disease. It is a prodrug, meaning it is inactive until it is metabolized in the body. Its primary medical application is in the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), particularly those undergoing dialysis. Unlike naturally occurring vitamin D, doxercalciferol is engineered to selectively activate the vitamin D receptor (VDR) with a reduced propensity for increasing calcium and phosphorus levels in the blood, which are common concerns in CKD patients.

This medication plays a crucial role in managing mineral and bone disorders associated with CKD, helping to maintain a healthier balance of calcium, phosphorus, and parathyroid hormone (PTH). By effectively lowering elevated PTH levels, doxercalciferol helps prevent the progressive bone disease and other systemic complications linked to SHPT.

How Does it Work?

Doxercalciferol exerts its therapeutic effects after being activated in the liver. Once administered, it is metabolized by the enzyme CYP27A1 into its active form, 1α,25-dihydroxyvitamin D2 (also known as active doxercalciferol or 1,25-dihydroxyvitamin D2). This active metabolite then binds to the vitamin D receptor (VDR), which is found in various tissues throughout the body, including the parathyroid glands.

The binding of active doxercalciferol to VDRs in the parathyroid glands leads to several beneficial actions:

• Suppression of Parathyroid Hormone (PTH) Synthesis: It directly inhibits the transcription of the PTH gene, thereby reducing the production and secretion of PTH.
• Regulation of Calcium and Phosphorus: While its primary goal is to lower PTH, doxercalciferol also helps to normalize calcium and phosphorus levels. It does so by indirectly influencing calcium and phosphorus absorption in the gut and reabsorption in the kidneys, though with less impact on these parameters compared to some other vitamin D analogs, which is advantageous in CKD patients prone to hypercalcemia and hyperphosphatemia.

By effectively lowering PTH levels, doxercalciferol helps to reverse the detrimental effects of SHPT on bone health and other organ systems in patients with CKD.

Medical Uses

The principal medical use of Doxercalciferol is the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD). This condition commonly develops as the kidneys lose their ability to convert vitamin D into its active form, leading to low calcium levels and consequently, overactivity of the parathyroid glands that produce excessive parathyroid hormone (PTH).

• Secondary Hyperparathyroidism in CKD Stages 3 and 4: Doxercalciferol is approved for patients with moderate to severe CKD (stages 3 and 4) who are not yet on dialysis, where it helps manage PTH levels and prevent the progression of bone and mineral disorders.
• Secondary Hyperparathyroidism in CKD Stage 5 (Dialysis Patients): It is also widely used in patients with end-stage renal disease (ESRD) undergoing hemodialysis or peritoneal dialysis. In these patients, SHPT is almost universal, and doxercalciferol is a vital component of their treatment regimen to control PTH, reduce bone disease, and improve overall outcomes.

The goal of treatment with doxercalciferol is to maintain PTH levels within a target range that minimizes the risks of bone disease and other complications associated with SHPT, without causing significant elevations in serum calcium or phosphorus.

Dosage

The dosage of Doxercalciferol is highly individualized and depends on the patient's specific condition, laboratory values (PTH, calcium, phosphorus), and response to therapy. It is available in both oral capsule and intravenous (IV) solution forms.

• Oral Doxercalciferol: Typically initiated at a low dose (e.g., 1 mcg or 2.5 mcg) once daily or three times per week. The dose is then carefully titrated upwards, usually every 2-4 weeks, based on PTH levels, serum calcium, and serum phosphorus.
• Intravenous Doxercalciferol: Administered three times per week, generally at the end of each dialysis session. Initial doses might range from 2 mcg to 4 mcg, with subsequent adjustments made based on the same laboratory parameters as the oral form.

Regular monitoring of serum calcium, phosphorus, and PTH is essential to ensure the therapeutic efficacy and safety of doxercalciferol. Dosing adjustments are frequently necessary to maintain optimal levels and minimize the risk of adverse effects like hypercalcemia or hyperphosphatemia. Patients should always follow their healthcare provider's instructions regarding dosage and administration.

Side Effects

While generally well-tolerated, Doxercalciferol can cause side effects, primarily related to its impact on calcium and phosphorus metabolism. The most common and clinically significant side effect is hypercalcemia (elevated calcium levels in the blood), which can lead to various symptoms and complications if not managed properly.

Common Side Effects:

• Hypercalcemia: Symptoms can include nausea, vomiting, constipation, dry mouth, increased thirst, frequent urination, muscle weakness, and fatigue. Severe hypercalcemia can be life-threatening.
• Hyperphosphatemia: Elevated phosphorus levels can also occur, especially if dietary phosphorus intake is not controlled or phosphate binders are not adequately used.
• Nausea and Vomiting: Gastrointestinal upset is possible.
• Edema: Swelling, particularly in the ankles and feet.
• Headache
• Malaise

Serious Side Effects:

Severe hypercalcemia is the most serious risk and requires immediate medical attention. Long-term uncontrolled hypercalcemia can lead to vascular calcification, kidney stones, and worsening renal function. Regular monitoring of serum calcium and phosphorus levels is crucial to prevent and manage these side effects.

Drug Interactions

Doxercalciferol can interact with several other medications, potentially altering its effectiveness or increasing the risk of adverse effects. It is crucial for patients to inform their healthcare provider about all medications, supplements, and herbal products they are taking.

• Thiazide Diuretics: Co-administration with thiazide diuretics can increase the risk of hypercalcemia.
• Digitalis Glycosides (e.g., Digoxin): Hypercalcemia, a potential side effect of doxercalciferol, can exacerbate arrhythmias in patients taking digitalis glycosides.
• Other Vitamin D Analogs: Concomitant use with other vitamin D analogs (e.g., calcitriol, paricalcitol) is generally not recommended due to an increased risk of hypercalcemia and hyperphosphatemia.
• Magnesium-Containing Antacids: In patients with chronic kidney disease, magnesium-containing antacids can lead to hypermagnesemia when used concurrently with doxercalciferol.
• Phosphate Binders: While often used together to manage phosphorus levels, the dosage of phosphate binders may need adjustment to prevent hyperphosphatemia when initiating or adjusting doxercalciferol.
• CYP24 Inhibitors: Medications that inhibit CYP24, an enzyme involved in vitamin D metabolism, could potentially increase levels of the active doxercalciferol metabolite, leading to an increased risk of hypercalcemia.

Close monitoring and dosage adjustments are often necessary when doxercalciferol is used with these interacting drugs.

FAQ

Q: Is Doxercalciferol a regular vitamin D supplement?

A: No, Doxercalciferol is a synthetic vitamin D analog and a prescription medication. It is specifically designed to treat secondary hyperparathyroidism in chronic kidney disease patients, and its use requires careful medical supervision and monitoring, unlike over-the-counter vitamin D supplements.

Q: How quickly does Doxercalciferol work to lower PTH?

A: The reduction in parathyroid hormone (PTH) levels with doxercalciferol therapy can be observed within a few weeks, but it may take several months of consistent treatment and dosage adjustments to achieve optimal and stable PTH levels within the target range.

Q: Can Doxercalciferol cure chronic kidney disease?

A: No, doxercalciferol does not cure chronic kidney disease. It is used to manage a specific complication of CKD, namely secondary hyperparathyroidism and its associated mineral and bone disorders. It helps improve the quality of life and reduce complications but does not affect the underlying kidney damage.

Q: What is secondary hyperparathyroidism?

A: Secondary hyperparathyroidism is a condition where the parathyroid glands produce too much parathyroid hormone (PTH) in response to persistently low calcium levels, often due to impaired kidney function and vitamin D metabolism in chronic kidney disease.

Products containing Doxercalciferol are available through trusted online pharmacies. You can browse Doxercalciferol-based medications at ShipperVIP or Medicenter.

Summary

Doxercalciferol is a vital synthetic vitamin D2 analog used to manage secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD). As a prodrug, it is activated in the liver to 1α,25-dihydroxyvitamin D2, which then binds to the vitamin D receptor (VDR) in the parathyroid glands. This action effectively suppresses the overproduction of parathyroid hormone (PTH), a common complication of CKD that can lead to severe bone disease and other systemic issues.

Available in oral and intravenous forms, doxercalciferol dosage is carefully individualized based on PTH, calcium, and phosphorus levels, requiring strict medical supervision. While effective, potential side effects, primarily hypercalcemia, necessitate regular monitoring. Awareness of drug interactions is also crucial for safe and effective treatment. Doxercalciferol plays a significant role in improving the quality of life and long-term outcomes for individuals living with CKD by addressing critical mineral and bone disorders.